JP7574223B2 - THR-βの調節物質およびその使用方法 - Google Patents

THR-βの調節物質およびその使用方法 Download PDF

Info

Publication number
JP7574223B2
JP7574223B2 JP2021566558A JP2021566558A JP7574223B2 JP 7574223 B2 JP7574223 B2 JP 7574223B2 JP 2021566558 A JP2021566558 A JP 2021566558A JP 2021566558 A JP2021566558 A JP 2021566558A JP 7574223 B2 JP7574223 B2 JP 7574223B2
Authority
JP
Japan
Prior art keywords
optionally substituted
group
formula
alkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021566558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532706A (ja
JP2022532706A5 (cg-RX-API-DMAC10.html
Inventor
バンディック,クーン
ラボワソン,ピエール,ジャン-マリー,ベルナール
マクゴワン,ダヴィド
デバル,ジェローム
Original Assignee
アリゴス セラピューティクス,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゴス セラピューティクス,インコーポレーテッド filed Critical アリゴス セラピューティクス,インコーポレーテッド
Publication of JP2022532706A publication Critical patent/JP2022532706A/ja
Publication of JP2022532706A5 publication Critical patent/JP2022532706A5/ja
Priority to JP2024180616A priority Critical patent/JP7844578B2/ja
Application granted granted Critical
Publication of JP7574223B2 publication Critical patent/JP7574223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2021566558A 2019-05-08 2020-05-07 THR-βの調節物質およびその使用方法 Active JP7574223B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180616A JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US62/845,252 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US62/944,052 2019-12-05
US202063005661P 2020-04-06 2020-04-06
US63/005,661 2020-04-06
PCT/US2020/031904 WO2020227549A1 (en) 2019-05-08 2020-05-07 MODULATORS OF THR-β AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180616A Division JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022532706A JP2022532706A (ja) 2022-07-19
JP2022532706A5 JP2022532706A5 (cg-RX-API-DMAC10.html) 2023-05-12
JP7574223B2 true JP7574223B2 (ja) 2024-10-28

Family

ID=70919081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566558A Active JP7574223B2 (ja) 2019-05-08 2020-05-07 THR-βの調節物質およびその使用方法
JP2024180616A Active JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180616A Active JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Country Status (32)

Country Link
US (3) US11091467B2 (cg-RX-API-DMAC10.html)
EP (2) EP4523692A3 (cg-RX-API-DMAC10.html)
JP (2) JP7574223B2 (cg-RX-API-DMAC10.html)
KR (1) KR102968107B1 (cg-RX-API-DMAC10.html)
CN (2) CN122036699A (cg-RX-API-DMAC10.html)
AU (1) AU2020267576B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021021718A2 (cg-RX-API-DMAC10.html)
CA (1) CA3139101A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002883A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021015698A2 (cg-RX-API-DMAC10.html)
DK (1) DK3965884T3 (cg-RX-API-DMAC10.html)
ES (1) ES3020290T3 (cg-RX-API-DMAC10.html)
FI (1) FI3965884T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20247637B (cg-RX-API-DMAC10.html)
HR (1) HRP20250384T1 (cg-RX-API-DMAC10.html)
HU (1) HUE070650T2 (cg-RX-API-DMAC10.html)
IL (1) IL287720A (cg-RX-API-DMAC10.html)
LT (1) LT3965884T (cg-RX-API-DMAC10.html)
MA (1) MA55890B1 (cg-RX-API-DMAC10.html)
MD (1) MD3965884T2 (cg-RX-API-DMAC10.html)
MX (1) MX2021013472A (cg-RX-API-DMAC10.html)
MY (1) MY210357A (cg-RX-API-DMAC10.html)
PE (1) PE20220255A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021552782A1 (cg-RX-API-DMAC10.html)
PL (1) PL3965884T3 (cg-RX-API-DMAC10.html)
PT (1) PT3965884T (cg-RX-API-DMAC10.html)
RS (1) RS66686B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202111552YA (cg-RX-API-DMAC10.html)
SI (1) SI3965884T1 (cg-RX-API-DMAC10.html)
TW (1) TWI855068B (cg-RX-API-DMAC10.html)
WO (1) WO2020227549A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202409114B (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) * 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3158379A1 (en) * 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
WO2021244582A1 (zh) * 2020-06-02 2021-12-09 成都康弘药业集团股份有限公司 新型甲状腺激素β受体激动剂
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
KR20230066408A (ko) * 2020-09-10 2023-05-15 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
EP4215524A4 (en) * 2020-09-17 2024-10-02 Sunshine Lake Pharma Co., Ltd. COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USES OF THE COMPOUND
US11793815B2 (en) 2020-11-06 2023-10-24 Aligos Therapeutics, Inc. Oxindoles and methods of use thereof
AU2021376281A1 (en) 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Pyridazinone derivatives as thyroid receptor agonists and uses thereof
CN114591300A (zh) * 2020-12-04 2022-06-07 南京圣和药业股份有限公司 作为THRβ激动剂的杂环化合物及其应用
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450B (zh) * 2020-12-30 2026-06-16 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
JP2024510935A (ja) * 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
WO2022184177A1 (zh) * 2021-03-04 2022-09-09 甫康(上海)健康科技有限责任公司 一种芳香化合物、其制备方法及其应用
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1,2,4-三嗪-3,5-二酮类化合物的盐型、晶型及其制备方法
TW202313615A (zh) * 2021-05-21 2023-04-01 大陸商深圳微芯生物科技股份有限公司 一種雜環化合物及其應用
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
US20250243491A1 (en) 2021-09-01 2025-07-31 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
CA3230382A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
TWI910297B (zh) * 2021-12-24 2026-01-01 大陸商廣東東陽光藥業股份有限公司 一種作為甲狀腺激素β受體激動劑的化合物及其用途
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN119137113A (zh) * 2022-02-10 2024-12-13 马德里加尔制药公司 THRβ类似物及其用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
WO2024182446A2 (en) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
US20240352464A1 (en) 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN121358734A (zh) * 2023-06-19 2026-01-16 西威埃医药技术(上海)有限公司 THR-β受体激动剂、其制备方法和其使用方法
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
CN117327057B (zh) * 2023-08-30 2026-03-03 南京雷正医药科技有限公司 一类作为甲状腺激素受体激动剂的三嗪二酮类化合物及其合成、用途
WO2025137568A1 (en) * 2023-12-21 2025-06-26 Aligos Therapeutics, Inc. Modulators of thr-beta and methods of use thereof
TW202604525A (zh) 2024-05-03 2026-02-01 美商艾利格斯醫療公司 製備THR-β調節劑之方法
WO2025252147A1 (zh) * 2024-06-07 2025-12-11 珠海联邦制药股份有限公司 一种甲状腺激素β受体激动剂的化合物及其应用
WO2026050911A1 (zh) * 2024-09-04 2026-03-12 西威埃医药技术(上海)有限公司 一种TR-β选择性激动剂的晶型、制备方法和应用
WO2026067791A1 (en) 2024-09-30 2026-04-02 Ascletis Pharma (China) Co., Limited 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives as thr-beta agonist or modulators for the treatment of obesity
US20260102403A1 (en) 2024-10-11 2026-04-16 Aligos Therapeutics, Inc. Oral formulations of thr-beta agonist
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases
CN120923503A (zh) * 2025-10-10 2025-11-11 吉斯凯(苏州)制药有限公司 具有杂环结构的化合物、THRβ受体激动剂及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501759A (ja) 2005-07-21 2009-01-22 エフ.ホフマン−ラ ロシュ アーゲー 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体
WO2010122980A1 (ja) 2009-04-20 2010-10-28 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
JP2010539209A (ja) 2007-09-20 2010-12-16 エフ.ホフマン−ラ ロシュ アーゲー 甲状腺ホルモンアナログのプロドラッグ
JP2015535817A (ja) 2012-09-17 2015-12-17 マドリガル・ファーマシューティカルズ・インコーポレーテッドMadrigal Pharmaceuticals,Inc. 甲状腺ホルモンアナログ及びその多形体の合成方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
CA2473162A1 (en) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
WO2004047827A1 (en) 2002-11-25 2004-06-10 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
JP2009521448A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
CN101506158A (zh) * 2006-06-28 2009-08-12 株式会社三和化学研究所 新6-5系二环式杂环衍生物及其医药用途
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
DK2695611T3 (en) 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions
EP3019196B1 (en) 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
MX2017008844A (es) 2015-01-09 2018-03-14 Gilead Apollo Llc Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
KR102444366B1 (ko) 2016-06-03 2022-09-19 케모센트릭스, 인크. 간 섬유화 치료 방법
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
SG11201907673YA (en) 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
US11808772B2 (en) 2017-07-19 2023-11-07 Bio-Rad Europe Gmbh Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status
WO2019099457A1 (en) 2017-11-14 2019-05-23 Quixgen, Inc. Benzodioxinone compounds
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
EP3765059A4 (en) 2018-03-12 2022-01-12 Yale University METHODS OF TREATMENT OR PREVENTION OF ACUTE RESPIRATORY SYNDROME
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
EP3806832A1 (en) 2018-06-14 2021-04-21 Alma Mater Studiorum - Università di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
US20210292304A1 (en) 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202615431A (zh) 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN119552152A (zh) * 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2020228577A1 (zh) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
CN112300133B (zh) 2019-07-31 2024-07-30 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
EP4019524A4 (en) 2019-08-19 2024-01-03 Hepagene Therapeutics (HK) Limited HETEROCYCLIC THR-BETA RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN112442013B (zh) 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021057791A1 (zh) 2019-09-24 2021-04-01 广东东阳光药业有限公司 一种作为甲状腺激素Beta受体激动剂的化合物及其用途
CN112707892A (zh) 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
CA3158379A1 (en) 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
MX2022012469A (es) 2020-04-06 2022-10-27 Basf Se Compuestos de imidazo-pirimidona como plaguicidas.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501759A (ja) 2005-07-21 2009-01-22 エフ.ホフマン−ラ ロシュ アーゲー 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体
JP2010539209A (ja) 2007-09-20 2010-12-16 エフ.ホフマン−ラ ロシュ アーゲー 甲状腺ホルモンアナログのプロドラッグ
WO2010122980A1 (ja) 2009-04-20 2010-10-28 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
JP2015535817A (ja) 2012-09-17 2015-12-17 マドリガル・ファーマシューティカルズ・インコーポレーテッドMadrigal Pharmaceuticals,Inc. 甲状腺ホルモンアナログ及びその多形体の合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KELLY, M. J. et al.,"Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile(MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia",Journal of Medicinal Chemistry,2014年,Vol. 57, No. 10,pp. 3912-3923,DOI: 10.1021/jm4019299

Also Published As

Publication number Publication date
EP4523692A2 (en) 2025-03-19
AU2020267576B2 (en) 2025-03-13
US11091467B2 (en) 2021-08-17
MD3965884T2 (ro) 2025-05-31
TWI855068B (zh) 2024-09-11
CN114096531B (zh) 2026-03-10
KR102968107B1 (ko) 2026-05-26
ES3020290T3 (en) 2025-05-22
US20250304561A1 (en) 2025-10-02
KR20220017917A (ko) 2022-02-14
MA55890B1 (fr) 2025-03-28
US20210355112A1 (en) 2021-11-18
EP4523692A3 (en) 2025-06-04
MY210357A (en) 2025-09-13
US20200354345A1 (en) 2020-11-12
BR112021021718A2 (pt) 2022-01-18
MA55890A (fr) 2022-03-16
JP2025011262A (ja) 2025-01-23
JP2022532706A (ja) 2022-07-19
MX2021013472A (es) 2022-01-06
WO2020227549A1 (en) 2020-11-12
FI3965884T3 (fi) 2025-04-02
RS66686B1 (sr) 2025-05-30
DK3965884T3 (da) 2025-03-31
SG11202111552YA (en) 2021-11-29
TW202108569A (zh) 2021-03-01
PH12021552782A1 (en) 2023-01-16
EP3965884A1 (en) 2022-03-16
LT3965884T (lt) 2025-04-10
PE20220255A1 (es) 2022-02-16
ZA202409114B (en) 2025-06-25
HRP20250384T1 (hr) 2025-05-23
US12180192B2 (en) 2024-12-31
AU2020267576A1 (en) 2021-12-09
PL3965884T3 (pl) 2025-05-05
JP7844578B2 (ja) 2026-04-13
WO2020227549A8 (en) 2021-05-27
PT3965884T (pt) 2025-03-31
CL2021002883A1 (es) 2022-10-28
GEAP202415821A (en) 2024-03-11
CA3139101A1 (en) 2020-11-12
CN114096531A (zh) 2022-02-25
HUE070650T2 (hu) 2025-06-28
SI3965884T1 (sl) 2025-05-30
CO2021015698A2 (es) 2022-01-17
GEP20247637B (en) 2024-06-25
CN122036699A (zh) 2026-05-15
EP3965884B1 (en) 2025-01-15
IL287720A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7844578B2 (ja) THR-βの調節物質およびその使用方法
TWI674260B (zh) 芳基烴受體(AhR)調節劑化合物
WO2018149284A1 (zh) 激酶抑制剂及其制备方法和用途
WO2021249519A1 (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2017507981A (ja) Trpm8拮抗剤としてのアザスピロ誘導体
WO2025161532A1 (zh) Pde4b抑制剂及其药物组合物和用途
JP2023550597A (ja) 甲状腺ホルモン受容体ベータ(TR-β)アゴニストとしての二環式ピリダジノン
US20180155344A1 (en) Tricyclic piperidine compounds
JP2023548541A (ja) オキシインドール及びその使用方法
HK40071114A (en) Modulators of thr-beta with a dioxo-1,2,4-triazyl head group
HK40071114B (en) Modulators of thr-beta with a dioxo-1,2,4-triazyl head group
EA047363B1 (ru) МОДУЛЯТОРЫ THR-β И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2023547306A (ja) アリールアミド化合物、それを含む医薬組成物、その製造方法及びそれらの使用
OA21036A (en) Modulators of Thr-ß and methods of use thereof.
CN116802176A (zh) 羟吲哚及其使用方法
WO2023109540A1 (zh) 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
BR112016020223B1 (pt) Composto, uso do mesmo, composição farmacêutica, e processo para a preparação da mesma

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241016

R150 Certificate of patent or registration of utility model

Ref document number: 7574223

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150